ME NewsWire/ Business Wire
LAUSANNE, Switzerland - Tuesday, February 11th 2014
Today,
Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A.,
a global leader focused on meeting the world’s increasing skin health
needs with a scientifically-proven broad range of innovative products.
The company will be formed by the acquisition of 50% of Galderma Pharma
S.A. (Galderma), subject to regulatory clearance. Galderma was
established in 1981 as a dermatology-focused, Swiss-based joint-venture
between Nestlé and L’Oréal S.A. (L’Oréal) and had sales of CHF 2.0
billion in calendar year 2013.
Nestlé chairman Peter
Brabeck-Letmathe said “Building on Nestlé’s historic strengths as a
science based Nutrition, Health & Wellness Company and through the
recent creation of Nestlé Health Science S.A., the company has
reinforced its strategic direction to offer nutritional solutions from
food & beverage to scientific products for a healthier life. By
creating Nestlé Skin Health S.A. and by leveraging Galderma’s current
portfolio, formulations and innovative research, Nestlé will now be able
to provide science-based solutions for skin conditions. We strive to
have a portfolio of innovative products that meet the full spectrum of
people’s skin health needs over the course of their lives and to provide
a holistic approach to people’s health.” The establishment of Nestlé
Skin Health will allow the emergence of a global leader that will
leverage Galderma’s and Nestlé’s commercial operations throughout the
world. Galderma’s Scientific Division, with laboratories located in
France, Sweden, United States, Japan and Switzerland, will become part
of Nestlé Skin Health and will actively collaborate with Nestlé’s global
R&D network. Galderma’s 33 commercial subsidiaries around the world
will continue to deliver scientifically-defined and medically-proven
products to patients and healthcare providers around the world under the
Galderma brand and organization.
Nestlé CEO Paul Bulcke said
that “Nestlé Skin Health will have a broad commercial and R&D
platform able to deliver state of the art solutions focused on
maintaining, treating and restoring the health of the skin. The new
company will be particularly effective working across different trade
channels to help people meet their skin health needs at a time when
access to medical care is getting more challenging due to resource
constraints.” He added “Nestlé will contribute its Bübchen line of baby
care products to Nestlé Skin Health and provide Galderma access to
innovative technologies from Nestlé’s R&D as well to help develop
Nestlé Skin Health’s future portfolio.”
Nestlé Skin Health will
have a full range of products for the skin, hair and nail including
self-medication drugs, quasi-drugs such as medicated soaps or
sunscreens, therapeutic skin care products, nutraceuticals, prescription
drugs and medical devices. Nestlé Skin Health, a wholly-owned
subsidiary of Nestlé, will become operational as soon as regulatory
requirements and competition authority clearance have been provided.
Humberto C. Antunes, who currently serves as President and CEO of
Galderma, will lead Nestlé Skin Health reporting to the company’s new
Board of Directors. Peter Brabeck-Letmathe will become Chairman and Paul
Bulcke Vice-chairman of the new Board of Directors of Nestlé Skin
Health, based in Switzerland.
On behalf of Galderma, Humberto C.
Antunes, CEO explained “this is good news for patients, consumers and
healthcare providers, and the thousands of Galderma employees throughout
the world. As part of Nestlé Skin Health, Galderma’s medical heritage
and portfolio can be expanded to meet the full range of skin health
needs, creating a new world leader focused on improving people’s lives.”
The
skin, the largest organ in the human body, plays an important role in
how we perceive ourselves and how others perceive us. Improving skin
health has a proven impact on well-being and quality of life and these
aspects, together with preventing, treating and curing medical
conditions related to the skin, are what Nestlé Skin Health aspires to
address.
About Nestlé Skin Health
Responding to increasing
consumer needs, Nestlé will extend its activities to include the field
of specialized, medical skin treatments through the creation of Nestlé
Skin Health S.A., a global leader focused on meeting the world’s
increasing skin health needs with a scientifically-proven broad range of
innovative products. Nestlé Skin Health S.A. will be managed as a
wholly-owned subsidiary of Nestlé S.A., with its own Board of Directors,
located in Lausanne, Switzerland. Upon the approval and completion of
Nestlé’s acquisition of the 50% stake of Galderma from L’Oréal, Galderma
will form the foundation of Nestlé Skin Health S.A.
About Galderma
A
global company exclusively dedicated to dermatology Galderma is a
global company founded in 1981 committed to delivering innovative
medical solutions to meet the dermatological needs of people throughout
their lifetime while serving healthcare professionals around the world.
The company has 33 wholly-owned affiliates with a worldwide network of
distributors and more than 5,000 employees. Galderma’s extensive product
portfolio is available in 80 countries and treats a range of
dermatological conditions including: acne, rosacea, onychomycosis,
psoriasis & steroid-responsive dermatoses, pigmentary disorders,
skin cancer and medical solutions for skin senescence.
With
approximately 19% of revenues invested each year to discover and develop
new products and access innovative technologies, the company is one of
the world’s leading investors in dermatology R&D. Five
state-of-the-art R&D centers and five manufacturing sites are
dedicated to providing a wide range of innovative medical solutions
which meet the highest standards of safety and efficacy.
Strategic
brands include Epiduo, Oracea, Clobex, Differin, Mirvaso,
Rozex/MetroGel, Silkis/Vectical, Tri-Luma, Loceryl, Cetaphil, Metvix,
Azzalure, Restylane and Emervel.
For more information, please visit Galderma’s website www.galderma.com.
<>
Contacts
Galderma
Media Contact:
Karin Falck, Phone: +41 79 722 6075
Public & Media Relations Officer
For any question, please contact communication@galderma.com
Permalink: http://www.me-newswire.net/news/10003/en
No comments:
Post a Comment